Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02922582 · ClinicalTrials.gov registry record · Phase 2

Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA

A Phase 2 study, sponsored by Pacira Pharmaceuticals.

Terminated
Registry status
Phase 2
Development phase
16
Enrollment target

NCT02922582 is a Phase 2 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02922582, a Phase 2 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.

TERMINATED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in subjects scheduled to undergo total knee arthroplasty (TKA).

Interventions

  • DRUG Tranexamic Acid
  • DRUG DepoTXA

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2016-10-28
Est. Completion 2017-11-27
Phase Phase 2

Sponsor

Pacira Pharmaceuticals

88 total trials

What the Registry Record Tells You About NCT02922582

The ClinicalTrials.gov registry entry for NCT02922582 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Tranexamic Acid is the first listed.

NCT02922582 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02922582 about?

NCT02922582 is a clinical study titled "Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA". This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in subjects scheduled to undergo total knee arthroplasty (TKA).

What is the current status of trial NCT02922582?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-10-28. Estimated completion is 2017-11-27.

What interventions are being tested in trial NCT02922582?

The interventions under investigation include: Tranexamic Acid (DRUG), DepoTXA (DRUG).

Who is sponsoring clinical trial NCT02922582?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.